Patients with both V600E mutations and microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) have poor prognosis. Currently, there are no specifically targeted first-line treatment options indicated for patients with mCRC whose tumors harbor both molecular aberrations. Pembrolizumab is a checkpoint inhibitor approved for the treatment of MSI-H/dMMR mCRC, and the BRAF inhibitor encorafenib, in combination with cetuximab, is approved for previously treated V600E-mutant mCRC. Combination of pembrolizumab with encorafenib and cetuximab may synergistically enhance antitumor activity in patients with V600E-mutant, MSI-H/dMMR mCRC. SEAMARK is a randomized phase II study comparing the efficacy of the combination of pembrolizumab with encorafenib and cetuximab versus pembrolizumab alone in patients with previously untreated V600E-mutant, MSI-H/dMMR mCRC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2022-1249 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.
Nat Med
January 2025
Vall d'Hebron Hospital Campus and Vall d'Hebron Institute of Oncology (VHIO), University of Vic - Central University of Catalonia, Barcelona, Spain.
Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study. Historically, first-line treatment of BRAF V600E-mutant mCRC with chemotherapy regimens has had limited efficacy. The phase 3 BREAKWATER study investigated EC+mFOLFOX6 versus standard of care (SOC) in patients with previously untreated BRAF V600E mCRC.
View Article and Find Full Text PDFPrognostic impact of depth of response and early tumour shrinkage in patients with -mutated metastatic colorectal cancer treated with targeted therapy.
Ther Adv Med Oncol
January 2025
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via Roma 67, Pisa 56126, Italy.
Background: Encorafenib plus cetuximab (EC) is the standard of care for pre-treated mutated metastatic colorectal cancer (mCRC). Depth of response (DpR) and early tumour shrinkage (ETS) previously showed a strong correlation with survival outcomes of first-line chemotherapy ± biological agents.
Objectives: We aimed to assess potential predictors of primary resistance to EC ± binimetinib (B) and relationships of DpR/ETS with survival outcomes and clinical characteristics.
The efficacy of targeted therapy and/or immunotherapy with or without chemotherapy in patients with colorectal cancer: A network meta-analysis.
Eur J Pharmacol
February 2025
Nanhai Hospital of Traditional Chinese Medicine, Jinan University, No.16, Guicheng South Fifth Road, Foshan, Guangdong, 528200, China; Jinan University, Guangzhou, 510632, China; Guangzhou University of Chinese Medicine, Guangzhou, 510006, China. Electronic address:
Background: The use of targeted drugs and immunotherapy has significantly impacted the treatment of Colorectal Cancer. However, horizontal comparison among various regimens is extremely rare. Therefore, we evaluated the survival efficacy of multiple treatment regimens of targeted therapy and/or immunotherapy with or without chemotherapy in patients with Colorectal Cancer.
View Article and Find Full Text PDFDetecting BRAF mutations in colorectal cancer in clinical practice: An Italian experts' position paper.
Crit Rev Oncol Hematol
November 2024
Department of Medicine - DIMED, University of Padua, Padua, Italy; Veneto Institute of Oncology IOV - IRCCS, Padua, Italy. Electronic address:
BRAF p.V600E exon 15 hotspot mutation can identify a molecular subgroup of metastatic colorectal cancer (mCRC) patients exhibiting poor prognosis under the conventional chemotherapy regimen. Recently, the chemotherapy-free combination of encorafenib and cetuximab has been approved as the standard of care for previously treated BRAF p.
View Article and Find Full Text PDFTriple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced -mutated non-small cell lung cancer patients.
Transl Lung Cancer Res
October 2024
Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Article Synopsis
- The study focuses on the effectiveness and safety of a triple-targeted therapy (dabrafenib, trametinib, and osimertinib) for advanced non-small cell lung cancer (NSCLC) patients who developed a V600E mutation after initially responding to EGFR-TKI treatment.
- A multi-center review of 13 NSCLC patients showed promising results, with an objective response rate of 61.5% and a disease control rate of 92.3%, alongside a median progression-free survival of 13.5 months.
- The research also included patient-derived organoids to assess drug response and next-generation sequencing to identify resistance mechanisms, highlighting significant tumor growth inhibition with the triple-targeted therapy compared to other reg
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!